Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic Considerations
Abstract
Acute myeloid leukemia (AML) in patients with end-stage renal disease (ESRD) requiring hemodialysis presents numerous challenges to clinicians, including selection of appropriate chemotherapy agents, safe dose adjustment, and supportive care management. Due to the lack of prospective studies in patients undergoing dialysis, it is difficult to determine the optimal therapeutic approach for this population. These patients are commonly excluded from large-scale AML clinical trials, which further complicates the determination of effective management strategies and associated toxicities. We present the case of a 51-year-old man with ESRD on hemodialysis who developed an adverse-risk AML (characterized by a BCL6 corepressor (BCOR) mutation with runt-related transcription factor 1 (RUNX1) and nuclear receptor-binding SET domain protein 1 (NSD1) abnormalities). Initial presentation was notable for profound pancytopenia without circulating blasts, although peripheral blood flow cytometry confirmed AML. Management required a multidisciplinary discussion with leukemia specialists, nephrology, and pharmacy. The patient was treated with azacitidine and venetoclax rather than intensive induction chemotherapy because of dialysis dependence, cardiovascular comorbidities, and anticipated toxicity. Azacitidine was administered after dialysis sessions, while venetoclax dosing was adjusted because of concomitant posaconazole prophylaxis. Repeat molecular testing no longer detected previously…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.